Kailera Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ronald C. Renaud Jr.
- Full Time Employees
- 145
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 180 Third Avenue, 4th Floor Waltham MA United States of America 02451
- IPO Date
- Apr 17, 2026
- CIK
- 0002096997
- Website
- kailera.com
- Similar Companies
- Business
- Kailera Therapeutics, Inc. is an American advanced clinical-stage biopharmaceutical company focused on obesity and related metabolic conditions. It develops a diversified portfolio of next-generation GLP-1-based therapies delivered via injectable and oral formats, with lead candidates advancing through global Phase 3 programs and a broader pipeline spanning additional GLP-1 receptor agonists and tri-agonist modalities. Kailera operates primarily in the United States with clinical development activities and collaborations extending to international sites, aiming to provide weight-management options across varied treatment journeys. The company is headquartered in Boston, Massachusetts, and was founded in 2024 to accelerate innovative obesity care solutions. Kailera’s core products and services comprise clinical-stage injectable and oral therapeutics targeting obesity, chronic weight management, and related metabolic comorbidities, including both peptide-based dual-agonist and tri-agonist mechanisms, as well as formulation development for sustained-release or daily-dose regimens; ongoing negotiations and partnerships with major life-sciences investors support its financing and collaboration strategy, while ongoing trials and potential future regulatory filings shape its growth trajectory. Kailera maintains an operating model that emphasizes clinical development, strategic alliances, and a pipeline-driven approach to bring next-generation obesity therapies to patients worldwide.
Company News
Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% – Here’s What Happened
Kailera Therapeutics (NASDAQ:KLRA) Sets New 12-Month Low – Time to Sell?
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval
Kailera Therapeutics to Participate in September Investor Conferences
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
2 GLP-1 Stocks That Could Double Your Money by 2031
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win
Why Is Kailera Therapeutics Stock Falling Tuesday?
Kailera's GLP-1 drug meets main goal of late-stage trials
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Biotech ETF Index Surges 10% After Rebalance
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference